Ravulizumab
Ravulizumab (INN;[1] trade name Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | Complement component 5 |
Clinical data | |
Trade names | Ultomiris |
Other names | ALXN1210 |
Routes of administration | intravenous infusion |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | various proteases |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6430H9888N1696O2028S48 |
Molar mass | 144938.56 g·mol−1 |
This drug was developed by Alexion Pharmaceuticals, Inc.[2]
It was approved by the US Food and Drug Administration in December 2018.[3] In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab.[4]
References
- World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ravulizumab, American Medical Association.
- FDA approves new treatment for adult patients with rare, life-threatening blood disease
- "EMA Positive Opinion - Ultomiris / ravulizumab, April 26, 2019" (PDF). ema.europa.eu. Retrieved 11 May 2019.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.